GSK Sells Haleon Shares Valued Around $1.24 Billion Through Discounted Placing
By Michael Susin
GSK said it has sold a stake in Haleon valued around 978 million pounds ($1.24 billion), reducing its stake in the consumer-healthcare business to around 4.2%.
The British pharmaceutical giant said Wednesday that it has sold 300 million Haleon shares at an offer price of 326 pence a share. This represents a discount of 2.3% from Tuesday's closing price of 333.6 pence prior to the announcement.
U.S. pharma giant Pfizer also holds a 32% stake in Haleon, which was spun out of GSK and Pfizer's consumer-healthcare business.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
January 17, 2024 02:29 ET (07:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth